Indication

Active lupus nephritis

Active lupus nephritis is an acute or relapsing autoimmune inflammatory glomerulonephritis occurring in patients with systemic lupus erythematosus, representing a major driver of chronic renal morbidity and mortality. Read more about Active lupus nephritis

5 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Active lupus nephritis therapies.

Showing 1–5 of 5 drugs

BENLYSTA (belimumab)

IMMUNOMODULATOR, B-LYMPHOCYTE STIMULATOR (BLYS)-SPEC INHIB·SYSTEMIC LUPUS ERYTHEMATOSUS·+1
GSK

BENLYSTA (belimumab)

IMMUNOMODULATOR, B-LYMPHOCYTE STIMULATOR (BLYS)-SPEC INHIB·SYSTEMIC LUPUS ERYTHEMATOSUS·+1
GSK

BENLYSTA (belimumab)

IMMUNOMODULATOR, B-LYMPHOCYTE STIMULATOR (BLYS)-SPEC INHIB·SYSTEMIC LUPUS ERYTHEMATOSUS·+1
GSK
Filter & compare in the drug finder →Opens the drug finder with Active lupus nephritis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Active lupus nephritis.

Active lupus nephritis is an acute or relapsing autoimmune inflammatory glomerulonephritis occurring in patients with systemic lupus erythematosus, representing a major driver of chronic renal morbidity and mortality.

It develops when circulating or in situ autoantibodies and immune complexes deposit within the renal mesangium, subendothelium, or subepithelial compartments, inciting complement cascade activation and local cellular infiltration.

Clinically and histopathologically, active disease is defined by ongoing renal inflammation manifesting as marked proteinuria, active urinary sediment with microscopic hematuria or cellular casts, declining glomerular filtration, and biopsy findings such as endocapillary proliferation, cellular crescents, or fibrinoid necrosis.

Personalize your experience

Follow Active lupus nephritis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it